La catena delle opzioni mostra i dati chiave delle opzioni azionarie di ALX Oncology Holdings a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per ALX Oncology Holdings..

ALX Oncology Holdings (NASDAQ:ALXO) Azioni, Catena delle Opzioni

ALX ONCOLOGY HOLDINGS INC

ALX Oncology Holdings

ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. The company is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.

ALX Oncology Holdings Inc. - Common Stock

ALX Oncology Holdings Inc

Earnings

Press Releases

ALX Oncology Reports First Quarter 2025 Financial Results and Provides Corporate Update

News

ALX Oncology to Host R&D Webcast Event Highlighting its Novel EGFR Targeting Antibody-Drug Conjugate, ALX2004, on May 20, 2025

ALX Oncology Highlights Differentiated Design, Preclinical Data and Development Plans for EGFR-Targeted ADC, ALX2004, in R&D Webcast Event

ALX Oncology to Present at the Jefferies 2025 Global Healthcare Conference

ALX Oncology to Report Second Quarter 2025 Financial Results on August 12, 2025

ALX Oncology Reports Second Quarter 2025 Financial Results and Provides Corporate Update

ALX Oncology Doses First Patient in Phase 1 Dose Escalation Trial Evaluating ADC ALX2004 for the Treatment of EGFR-Expressing Solid Tumors

ALX Oncology to Participate in Upcoming Investor Conferences in September

Management

ALX Oncology Appoints Board Member Barbara Klencke, M.D., as Interim Chief Medical Officer

ALX Oncology to Present Updated Data from Phase 2 ASPEN-06 Trial, Highlighting CD47 Expression as a Predictive Biomarker in HER2+ Gastric Cancer, at 40th Society for Immunotherapy of Cancer (SITC) Annual Meeting

ALXO

Adagene Inc. - ADS, each representing 1.25 ordinary shares

Adagene

Adverum Biotechnologies, Inc. - Common Stock

Adverum Biotechnologies

Armata Pharmaceuticals, Inc. Common Stock

Armata Pharmaceuticals

Atara Biotherapeutics, Inc. - Common Stock

Atara Biotherapeutics

aTyr Pharma

Burning Rock Biotech Limited - American Depositary Shares

Burning Rock Biotech

Clene

Connect Biopharma Holdings Limited - Ordinary Shares

Connect Biopharma Hldgs

Coya Therapeutics

Entera Bio

EXoZymes

InflaRx

Insight Molecular Diagnostics Inc. - Common Stock

Insight Molecular

Immix Biopharma

Immunic

Kalaris Therapeutics, Inc. - Common Stock

Kalaris Therapeutics

Lite Strategy

Macrogenics

Metagenomi

NewAmsterdam Pharma Company N.V. - Warrant

NewAmsterdam Pharma Co

Quince Therapeutics

Spruce Biosciences

Shattuck Labs

Unicycive Therapeutics, Inc. - Common Stock

Unicycive Therapeutics

Whitehawk Therapeutics, Inc. - Common Stock

Comments

ALX Oncology Holdings

ALX Oncology Holdings (ALXO) Opzioni

ALX Oncology Holdings (NASDAQ:ALXO) Azioni, Catena delle Opzioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO